Key Highlights
- Matica Bio partners with Mongoose Bio to develop and produce lentivirus for TCR-T therapies.
- Focus on cancer treatment, leveraging advanced viral vector manufacturing.
- The collaboration advances Mongoose Bio’s TCR-T therapies into clinical trials.
- Texas biotech ecosystem growth supported through this strategic partnership.
Source: Business Wire
Notable Quotes
- “We are honored to collaborate with a team that shares our dedication to improving patient outcomes and advancing the frontiers of cancer treatment.” — Paul Kim, CEO at Matica Bio
- “We are pleased to be working with Matica Bio on viral vector manufacturing to advance our novel TCR-T therapies into the clinic.” — Neil Warma, President and CEO at Mongoose Bio
SoHC's Take
This partnership represents a vital step in the development of TCR-T cell therapies, underscoring the rising prominence of Texas in the biotech landscape. The collaboration between Matica Bio and Mongoose Bio not only advances cutting-edge cancer treatments but also solidifies Matica Bio’s role as a critical CDMO within the rapidly expanding biocluster in Texas. This alliance is poised to significantly impact the global oncology market, particularly as both companies continue to push the boundaries of cellular immunotherapy.
